Robert W. Duggan

CIK: 0001055919

Transaction Breakdown

Open Market Buys (P)13 (43.3%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)1 (3.3%)

Derivative conversions

Awards (A)12 (40.0%)

Compensation grants

Other (G, F, J, C, D, …)4 (13.3%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

PLSE

PULSE BIOSCIENCES, INC.

Director10% Owner

SMMT

Summit Therapeutics Inc.

DirectorOfficer10% Owner

Discretionary Trading P&L

Holdings

Transaction History (30 total)

SMMT
Summit Therapeutics Inc.
Jun 12, 2026
Purchase(P)
Direct
3.8M shares at avg. $13.12$50.0M
PLSE
PULSE BIOSCIENCES, INC.
Jun 11, 2026
Award(A)
Stock Option (right to buy)
Direct
30K shares-
PLSE
PULSE BIOSCIENCES, INC.
Jun 11, 2026
Award(A)
Stock Option (right to buy)
Direct
12.5K shares-
SMMT
Summit Therapeutics Inc.
Jun 4, 2026
Purchase(P)
Indirect
100K shares at avg. $14.60$1.5M
PLSE
PULSE BIOSCIENCES, INC.
May 11, 2026
Purchase(P)
Direct
660.2K shares at avg. $19.69$13.0M
SMMT
Summit Therapeutics Inc.
Jan 2, 2026
Award(A)
Stock Option (right to buy)
Direct
11.2K shares at avg. $8.76-
SMMT
Summit Therapeutics Inc.
Oct 21, 2025
Purchase(P)
Indirect
26.7K shares at avg. $18.74$500K
SMMT
Summit Therapeutics Inc.
Oct 21, 2025
Award(A)
Indirect
266.8K shares at avg. $18.74$5.0M
SMMT
Summit Therapeutics Inc.
Oct 21, 2025
Award(A)
Direct
14M shares at avg. $18.74$262.0M
SMMT
Summit Therapeutics Inc.
Sep 11, 2025
Purchase(P)
Direct
5K shares at avg. $18.07$90K
PLSE
PULSE BIOSCIENCES, INC.
Sep 10, 2025
Purchase(P)
Direct
34.7K shares at avg. $14.66$508K
SMMT
Summit Therapeutics Inc.
Sep 10, 2025
Purchase(P)
Direct
333.4K shares at avg. $17.68$5.9M
PLSE
PULSE BIOSCIENCES, INC.
Aug 15, 2025
Award(A)
Stock Option (right to buy)
Direct
20.8K shares-
PLSE
PULSE BIOSCIENCES, INC.
Aug 15, 2025
Award(A)
Stock Option (right to buy)
Direct
30K shares-
SMMT
Summit Therapeutics Inc.
May 30, 2025
Exercise(M)
Direct
74.5K shares at avg. $2.64$197K
SMMT
Summit Therapeutics Inc.
Apr 29, 2025
Award(A)
Stock Option (right to buy)
Indirect
400K shares-
SMMT
Summit Therapeutics Inc.
Apr 29, 2025
Award(A)
Stock Option (right to buy)
Indirect
1M shares-
SMMT
Summit Therapeutics Inc.
Apr 29, 2025
Award(A)
Stock Option (right to buy)
Indirect
9.6M shares-
SMMT
Summit Therapeutics Inc.
Apr 8, 2025
In-the-Money(X)
Direct
4M shares at avg. $1.58$6.3M
SMMT
Summit Therapeutics Inc.
Jan 2, 2025
Award(A)
Stock Option (right to buy)
Direct
10.7K shares at avg. $9.18-
PLSE
PULSE BIOSCIENCES, INC.
Dec 18, 2024
In-the-Money(X)
Direct
5.2M shares at avg. $11.00$57.1M
PLSE
PULSE BIOSCIENCES, INC.
Dec 18, 2024
In-the-Money(X)
Indirect
49.3K shares at avg. $11.00$542K
PLSE
PULSE BIOSCIENCES, INC.
Dec 18, 2024
In-the-Money(X)
Indirect
69K shares at avg. $11.00$759K
PLSE
PULSE BIOSCIENCES, INC.
Dec 13, 2024
Purchase(P)
Direct
55.3K shares at avg. $17.18$949K
PLES
PULSE BIOSCIENCES, INC.
Dec 12, 2024
Purchase(P)
Direct
45.4K shares at avg. $17.13$778K

		Type	Shares	Price		Ownership
Jun 12, 2026	SMMT Summit Therapeutics Inc.	Purchase(P)	3,810,000	$13.12	$49,987,200	Direct
Jun 11, 2026	PLSE PULSE BIOSCIENCES, INC.	Award(A) Stock Option (right to buy)	30,000	-	-	Direct
Jun 11, 2026	PLSE PULSE BIOSCIENCES, INC.	Award(A) Stock Option (right to buy)	12,495	-	-	Direct
Jun 4, 2026	SMMT Summit Therapeutics Inc.	Purchase(P)	100,000	$14.60	$1,460,000	Indirect
May 11, 2026	PLSE PULSE BIOSCIENCES, INC.	Purchase(P)	660,233	$19.69	$12,999,988	Direct
Jan 2, 2026	SMMT Summit Therapeutics Inc.	Award(A) Stock Option (right to buy)	11,232	$8.76	-	Direct
Oct 21, 2025	SMMT Summit Therapeutics Inc.	Purchase(P)	26,680	$18.74	$499,983	Indirect
Oct 21, 2025	SMMT Summit Therapeutics Inc.	Award(A)	266,808	$18.74	$4,999,982	Indirect
Oct 21, 2025	SMMT Summit Therapeutics Inc.	Award(A)	13,980,789	$18.74	$261,999,986	Direct
Sep 11, 2025	SMMT Summit Therapeutics Inc.	Purchase(P)	5,000	$18.07	$90,350	Direct
Sep 10, 2025	PLSE PULSE BIOSCIENCES, INC.	Purchase(P)	34,659	$14.66	$508,101	Direct
Sep 10, 2025	SMMT Summit Therapeutics Inc.	Purchase(P)	333,394	$17.68	$5,894,406	Direct
Aug 15, 2025	PLSE PULSE BIOSCIENCES, INC.	Award(A) Stock Option (right to buy)	20,792	-	-	Direct
Aug 15, 2025	PLSE PULSE BIOSCIENCES, INC.	Award(A) Stock Option (right to buy)	30,000	-	-	Direct
May 30, 2025	SMMT Summit Therapeutics Inc.	Exercise(M)	74,545	$2.64	$196,799	Direct
Apr 29, 2025	SMMT Summit Therapeutics Inc.	Award(A) Stock Option (right to buy)	400,000	-	-	Indirect
Apr 29, 2025	SMMT Summit Therapeutics Inc.	Award(A) Stock Option (right to buy)	1,040,000	-	-	Indirect
Apr 29, 2025	SMMT Summit Therapeutics Inc.	Award(A) Stock Option (right to buy)	9,590,558	-	-	Indirect
Apr 8, 2025	SMMT Summit Therapeutics Inc.	In-the-Money(X)	3,985,055	$1.58	$6,296,387	Direct
Jan 2, 2025	SMMT Summit Therapeutics Inc.	Award(A) Stock Option (right to buy)	10,724	$9.18	-	Direct
Dec 18, 2024	PLSE PULSE BIOSCIENCES, INC.	In-the-Money(X)	5,187,824	$11.00	$57,066,064	Direct
Dec 18, 2024	PLSE PULSE BIOSCIENCES, INC.	In-the-Money(X)	49,312	$11.00	$542,432	Indirect
Dec 18, 2024	PLSE PULSE BIOSCIENCES, INC.	In-the-Money(X)	69,020	$11.00	$759,220	Indirect
Dec 13, 2024	PLSE PULSE BIOSCIENCES, INC.	Purchase(P)	55,256	$17.18	$949,298	Direct
Dec 12, 2024	PLES PULSE BIOSCIENCES, INC.	Purchase(P)	45,404	$17.13	$777,771	Direct

1-25 of 30 transactions

About DUGGAN ROBERT W

DUGGAN ROBERT W (SEC CIK 0001055919) files insider reports with the SEC as Director of PULSE BIOSCIENCES, INC. (PLSE) and Co-Chief Executive Officer of Summit Therapeutics Inc. (SMMT).

Signal8 holds 19 ownership filings by DUGGAN ROBERT W, all Form 4s, filed between Sep 13, 2024 and Jun 15, 2026. Those filings report 30 transactions, from Sep 11, 2024 to Jun 12, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on DUGGAN ROBERT W's filings is in MIAMI, FL.

Recent filings by DUGGAN ROBERT W

Jun 12, 2026: Open-market purchase of SMMT shares (Form 4, code P).
Jun 11, 2026: Grants or awards of PLSE derivative securities (2 lines, Form 4, code A).
Jun 4, 2026: Open-market purchase of SMMT shares (Form 4, code P).
May 11, 2026: Open-market purchase of PLSE shares (Form 4, code P).
Jan 2, 2026: Grant or award of SMMT derivative securities (Form 4, code A).

Other insiders filing for PULSE BIOSCIENCES, INC. (PLSE)

Teplitsky Liane Rae, Chief Operating Officer
Skinner Jon, Chief Financial Officer
Zanganeh Mahkam, Director
van den Broek Richard, Director
Soni Manmeet Singh, Director
Sainz Maria, Director

How to read Form 4 transaction codes